TY - JOUR
T1 - Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults
AU - Vidal-Cortés, Pablo
AU - Martin-Loeches, Ignacio
AU - Rodríguez, Alejandro
AU - Bou, German
AU - Cantón, Rafael
AU - Díaz Santos, Emilio
AU - De la Fuente, Carmen
AU - Torre-Cisneros, Julián
AU - Nuvials, Francisco Xavier
AU - Salavert, Miguel
AU - Aguilar, Gerardo
AU - Nieto, Mercedes
AU - Ramírez, Paula
AU - Borges, Marcio
AU - Soriano, Cruz
AU - Ferrer, Ricard
AU - Maseda, Emilio
AU - Zaragoza, Rafael
PY - 2022
Y1 - 2022
N2 - Infections due to Klebsiella pneumoniae have been increasing in intensive care units (ICUs) in the last decade. Such infections pose a serious problem, especially when antimicrobial resistance is present. We created a task force of experts, including specialists in intensive care medicine, anaesthesia, microbiology and infectious diseases, selected on the basis of their varied experience in the field of nosocomial infections, who conducted a comprehensive review of the recently published literature on the management of carbapenemase-producing Enterobacterales (CPE) infections in the intensive care setting from 2012 to 2022 to summarize the best available treatment. The group established priorities regarding management, based on both the risk of developing infections caused by K. pneumoniae and the risk of poor outcome. Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
AB - Infections due to Klebsiella pneumoniae have been increasing in intensive care units (ICUs) in the last decade. Such infections pose a serious problem, especially when antimicrobial resistance is present. We created a task force of experts, including specialists in intensive care medicine, anaesthesia, microbiology and infectious diseases, selected on the basis of their varied experience in the field of nosocomial infections, who conducted a comprehensive review of the recently published literature on the management of carbapenemase-producing Enterobacterales (CPE) infections in the intensive care setting from 2012 to 2022 to summarize the best available treatment. The group established priorities regarding management, based on both the risk of developing infections caused by K. pneumoniae and the risk of poor outcome. Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
KW - carbapenemase-producing Enterobacterales (CPE)
KW - Klebsiella pneumoniae
KW - KPC
KW - VAP
KW - Nosocomial pneumonia
KW - Ceftazidime-avibactam
KW - Imipenem-relebactam
KW - Meropenem-vaborbactam
KW - Cefiderocol
KW - ICU
UR - https://www.scopus.com/pages/publications/85138553722
U2 - 10.3390/antibiotics11091160
DO - 10.3390/antibiotics11091160
M3 - Article
C2 - 36139940
SN - 2079-6382
VL - 11
JO - Antibiotics
JF - Antibiotics
IS - 9
ER -